Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective
For more than a decade, S-1 has been investigated aggressively against non-small cell lung cancer (NSCLC) in Japan. Recently, two randomized phase III trials of S-1 combined with cisplatin (CDDP) or carboplatin (CBDCA) compared with the standard platinum doublet chemotherapy were reported. S-1 and C...
Main Author: | Koji Takeda |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2013-09-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834013500702 |
Similar Items
-
Clinical development of nintedanib for advanced non-small-cell lung cancer
by: Takeda M, et al.
Published: (2015-11-01) -
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
by: Togashi Y, et al.
Published: (2014-07-01) -
The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer
by: Aleksandra Bożyk, et al.
Published: (2022-10-01) -
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
by: Mathieu Césaire, et al.
Published: (2022-06-01) -
Perspectives in Surgery of Oligometastatic Non-Small-Cell Lung Cancer
by: Fabio Villa, et al.
Published: (2015-03-01)